Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11323036 | 0.79 | UGT2B7 (0.50) | UGT2B7MEN1KMT2AATMCA1 | |
| SCHEMBL19684213 | 0.76 | UGT2B7 (0.56) | UGT2B7MEN1KMT2AATMCA1 | |
| SCHEMBL3041531 | 0.76 | TSHR (0.57) | UGT2B7MEN1KMT2AATMSLC6A2 | |
| SCHEMBL7872332 | 0.76 | UGT2B7 (0.47) | UGT2B7MEN1KMT2AATMCA1 | |
| SCHEMBL27536762 | 0.76 | TSHR (0.57) | UGT2B7MEN1KMT2AATMSLC6A2 | |
| SCHEMBL10928088 | 0.76 | TRPA1 (0.57) | UGT2B7MEN1KMT2AATMCA1 | |
| SCHEMBL10924402 | 0.76 | UGT2B7 (0.47) | UGT2B7MEN1KMT2AATMCA1 | |
| SCHEMBL10399050 | 0.76 | UGT2B7 (0.57) | UGT2B7MEN1KMT2AATMCA1 | |
| SCHEMBL17455440 | 0.76 | UGT2B7 (0.57) | UGT2B7MEN1KMT2AATMCA1 | |
| SCHEMBL28889063 | 0.74 | ALDH1A1 (0.46) | UGT2B7CA1CA2SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581495-B1 | 4-aryl-4-(naphth-1-ylmethylamino)methyl-piperidine compounds and their use | ASTRAZENECA AB (SE) | 2007-04-18 | — | — | EP | disclosed |
| US-20060058352-A1 | Piperidine amine compounds and their use | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-20050245572-A1 | Naphthyl ether compounds and their use | OLINK AB (SE) | 2005-11-03 | — | — | US | disclosed |
| EP-1581495-A1 | PIPERIDINE AMINE COMPOUNDS AND THEIR USE | AstraZeneca AB (SE) | 2005-10-05 | — | — | EP | disclosed |
| EP-1546101-A1 | NAPHTHYL ETHER COMPOUNDS AND THEIR USE | AstraZeneca AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004056771-A1 | PIPERIDINE AMINE COMPOUNDS AND THEIR USE | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004022539-A1 | NAPHTHYL ETHER COMPOUNDS AND THEIR USE | ASTRAZENECA AB (SE) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058352-A1 | Piperidine amine compounds and their use | HRH3, H1-5, H1-0 | UGT2B7 324/4885MEN1 2413/4885KMT2A 245/4885 |
| US-20050245572-A1 | Naphthyl ether compounds and their use | NR4A1, NPM1, H1-4 | UGT2B7 139/4885MEN1 1083/4885KMT2A 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.